Physician
Prime Healthcare Centinela, LLC
Prime Healthcare Centinela, LLC was paid $50.16M by Medicaid between Jan 2018 and Dec 2024, across 252 billing codes. Its largest line is 0111, — 54% of everything it billed.
33Billing provider infoPRIME HEALTHCARE CENTINELA, LLC
INGLEWOOD, CA 90301
INGLEWOOD, CA 90301
33aNPI1336328244assigned 10/26/2007
33bProvider typeNeonatal-Perinatal Medicine Physician
28Total paid$50.16M
24GClaims1,098,085
24DCodes billed252
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Neonatal-Perinatal Medicine Physician providers in California
Rank by total paid#1 of 80
Median peer was paid$66K
This provider vs. median761×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DOAN, CHRISTOPHER controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 232,890 | $15.78M | |
| 2019 | 171,414 | $9.21M | |
| 2020 | 125,028 | $4.30M | |
| 2021 | 130,599 | $5.56M | |
| 2022 | 156,405 | $6.18M | |
| 2023 | 152,291 | $4.91M | |
| 2024incomplete | 129,458 | $4.22M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0111 | 54% | 8,111 | 7,380 | $27.21M | |
| 0450 | Emergency room services | 8.1% | 111,855 | 98,023 | $4.08M |
| 0206 | 5.9% | 1,275 | 1,178 | $2.96M | |
| 0112 | 2.0% | 647 | 622 | $989K | |
| 70450 | Computed tomography, head or brain; without contrast material | 1.9% | 9,957 | 9,557 | $938K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.4% | 15,522 | 14,576 | $721K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.3% | 31,291 | 28,187 | $629K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.2% | 12,896 | 10,485 | $581K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1.0% | 2,344 | 2,222 | $509K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.0% | 11,045 | 8,365 | $506K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 5,442 | 5,248 | $475K |
| Z7502 | <1% | 10,617 | 10,436 | $394K |
240 more codes
| J3490 | Unclassified drugs | <1% | 44,929 | $372K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 6,182 | $362K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 12,509 | $359K |
| 80053 | Comprehensive metabolic panel | <1% | 45,407 | $356K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 1,756 | $330K |
| 71045 | Radiologic examination, chest; single view | <1% | 28,518 | $306K |
| 0200 | <1% | 275 | $294K | |
| 0250 | <1% | 58,822 | $285K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 52,997 | $279K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 14,217 | $271K |
| 0300 | <1% | 15,887 | $265K | |
| 99284 | Emergency room visit (serious) | <1% | 3,145 | $253K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 10,899 | $250K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 1,386 | $246K |
| 99199 | Unlisted special service, procedure or report | <1% | 6,164 | $242K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,838 | $230K |
| 0270 | <1% | 39,655 | $218K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,723 | $199K |
| 70486 | <1% | 1,577 | $195K | |
| 83880 | <1% | 9,307 | $181K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,858 | $180K |
| 99283 | Emergency room visit (moderate) | <1% | 2,857 | $175K |
| 0171 | Inj, epinephrine (belcher) | <1% | 447 | $171K |
| 84484 | <1% | 17,428 | $147K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 6,064 | $139K |
| 93970 | <1% | 995 | $132K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 20,299 | $127K |
| 0762 | <1% | 1,831 | $125K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,327 | $118K |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 1,701 | $112K |
| 76801 | <1% | 2,007 | $104K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,581 | $103K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 14,257 | $100K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 10,816 | $99K |
| 76830 | Ultrasound, transvaginal | <1% | 1,974 | $95K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,395 | $94K |
| 80305 | <1% | 10,758 | $90K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 923 | $88K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,986 | $87K |
| 83690 | <1% | 16,626 | $86K | |
| 90715 | <1% | 2,724 | $78K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,885 | $75K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 4,700 | $74K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,021 | $73K |
| 81025 | <1% | 19,228 | $73K | |
| Z7610 | <1% | 5,246 | $72K | |
| 93971 | <1% | 761 | $61K | |
| 0272 | <1% | 17,818 | $55K | |
| 0360 | <1% | 734 | $52K | |
| 0301 | <1% | 11,449 | $48K | |
| 73030 | <1% | 2,356 | $48K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,331 | $47K |
| 73130 | <1% | 2,129 | $47K | |
| 81003 | <1% | 28,902 | $46K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 7,284 | $46K |
| 73610 | <1% | 1,944 | $42K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,653 | $42K |
| 73630 | <1% | 2,083 | $41K | |
| 85610 | <1% | 12,938 | $40K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 6,701 | $38K |
| 73562 | <1% | 1,840 | $37K | |
| 83605 | <1% | 4,221 | $35K | |
| 0271 | <1% | 14,070 | $33K | |
| 87040 | <1% | 3,049 | $33K | |
| 0160 | <1% | 437 | $33K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,978 | $32K |
| 72100 | <1% | 1,181 | $32K | |
| J2704 | Injection, propofol, 10 mg | <1% | 437 | $32K |
| 84703 | <1% | 7,070 | $32K | |
| 84702 | <1% | 3,278 | $32K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,342 | $30K |
| 0710 | <1% | 1,977 | $29K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,178 | $26K |
| 0002A | <1% | 678 | $24K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 165 | $23K |
| 0001A | <1% | 649 | $22K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 32,285 | $22K |
| 73110 | <1% | 997 | $22K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,365 | $21K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 266 | $21K |
| 86850 | <1% | 4,613 | $20K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,429 | $19K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,539 | $18K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,362 | $18K |
| Z9725 | <1% | 410 | $17K | |
| 59025 | Fetal non-stress test | <1% | 1,028 | $17K |
| 0636 | <1% | 3,524 | $17K | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 2,243 | $16K |
| 85379 | <1% | 2,010 | $16K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 937 | $16K |
| J1815 | Injection, insulin, per 5 units | <1% | 197 | $15K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,187 | $14K |
| 73590 | <1% | 803 | $14K | |
| 87430 | <1% | 1,913 | $13K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 230 | $13K |
| 85730 | <1% | 2,897 | $12K | |
| 73560 | <1% | 666 | $12K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 306 | $12K |
| 82962 | <1% | 5,576 | $12K | |
| 87186 | <1% | 1,793 | $12K | |
| 86901 | <1% | 4,701 | $12K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,279 | $11K |
| 80320 | <1% | 1,727 | $10K | |
| 86900 | <1% | 4,683 | $10K | |
| 87070 | <1% | 1,731 | $10K | |
| 87077 | <1% | 1,974 | $10K | |
| 84145 | <1% | 678 | $10K | |
| 73502 | <1% | 363 | $9K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,674 | $9K |
| 99406 | <1% | 955 | $9K | |
| A4649 | Surgical supply; miscellaneous | <1% | 6,758 | $9K |
| 0306 | <1% | 7,109 | $8K | |
| 93976 | <1% | 51 | $8K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,926 | $8K |
| 96376 | <1% | 1,102 | $8K | |
| 73080 | <1% | 363 | $7K | |
| 0730 | <1% | 8,190 | $7K | |
| 0278 | <1% | 418 | $7K | |
| 80076 | <1% | 1,484 | $7K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,472 | $7K |
| 0004A | <1% | 160 | $6K | |
| 80185 | <1% | 496 | $6K | |
| 73090 | <1% | 338 | $6K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,279 | $6K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 563 | $6K |
| 82550 | <1% | 1,226 | $6K | |
| 76818 | <1% | 254 | $6K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 576 | $5K |
| 29125 | <1% | 257 | $4K | |
| 0214 | <1% | 12 | $4K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 386 | $4K |
| 0255 | <1% | 1,863 | $4K | |
| 74018 | <1% | 254 | $4K | |
| 0258 | <1% | 5,135 | $3K | |
| 87420 | <1% | 666 | $3K | |
| 82805 | <1% | 140 | $3K | |
| 0324 | <1% | 8,200 | $3K | |
| 70496 | <1% | 12 | $3K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 218 | $3K |
| 83735 | <1% | 699 | $3K | |
| 82140 | <1% | 326 | $3K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 586 | $3K |
| 10060 | <1% | 153 | $3K | |
| L1830 | Knee orthosis, immobilizer, canvas longitudinal, prefabricated, off-the-shelf | <1% | 41 | $3K |
| 99070 | <1% | 620 | $2K | |
| J1165 | Injection, phenytoin sodium, per 50 mg | <1% | 41 | $2K |
| 94644 | <1% | 156 | $2K | |
| 0801 | <1% | 75 | $2K | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 213 | $2K |
| 0351 | <1% | 2,489 | $2K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 33 | $2K |
| 96367 | <1% | 73 | $2K | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 1,600 | $2K |
| 12001 | <1% | 89 | $2K | |
| 0352 | <1% | 2,795 | $2K | |
| A4217 | Sterile water/saline, 500 ml | <1% | 231 | $2K |
| 72131 | <1% | 17 | $1K | |
| 80165 | <1% | 173 | $1K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 79 | $1K |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 125 | $1K |
| 73140 | <1% | 108 | $1K | |
| 0305 | <1% | 10,898 | $1K | |
| 82010 | <1% | 221 | $1K | |
| 70498 | <1% | 13 | $1K | |
| 82375 | <1% | 143 | $1K | |
| 12002 | <1% | 63 | $1K | |
| 0483 | <1% | 3,485 | $1K | |
| 71101 | <1% | 41 | $986.64 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 273 | $969.86 |
| 81001 | <1% | 548 | $948.23 | |
| 0920 | <1% | 3,887 | $920.05 | |
| 0370 | <1% | 695 | $904.98 | |
| 12011 | <1% | 53 | $894.80 | |
| 0350 | <1% | 633 | $889.59 | |
| 80156 | <1% | 109 | $866.86 | |
| 87210 | <1% | 220 | $713.47 | |
| 80329 | <1% | 469 | $678.71 | |
| 76857 | <1% | 26 | $617.52 | |
| 0341 | <1% | 386 | $572.12 | |
| E0114 | Crutches underarm, other than wood, adjustable or fixed, pair, with pads, tips and handgrips | <1% | 16 | $565.08 |
| 80184 | <1% | 93 | $564.17 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 97 | $535.70 |
| 82947 | <1% | 288 | $526.70 | |
| J7610 | Albuterol, inhalation solution, compounded product, administered through dme, concentrated form, 1 mg | <1% | 50 | $524.73 |
| 82553 | <1% | 43 | $518.95 | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 64 | $511.93 |
| 96368 | <1% | 36 | $466.75 | |
| 76870 | <1% | 15 | $463.76 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 41 | $446.13 |
| 0420 | <1% | 1,938 | $413.17 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 69 | $390.50 |
| 36600 | <1% | 46 | $381.03 | |
| 72040 | <1% | 15 | $366.99 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 182 | $358.31 |
| 0611 | <1% | 575 | $303.67 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 62 | $274.97 |
| 85027 | <1% | 60 | $270.23 | |
| 0740 | <1% | 131 | $260.03 | |
| 72170 | <1% | 12 | $235.15 | |
| 73060 | <1% | 12 | $231.97 | |
| 0307 | <1% | 7,185 | $209.37 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 48 | $197.73 |
| 73552 | <1% | 12 | $186.66 | |
| 0402 | <1% | 2,802 | $184.30 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 51 | $165.02 |
| 0921 | <1% | 398 | $159.64 | |
| 0430 | <1% | 539 | $158.81 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 43 | $154.25 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 33 | $130.93 |
| 0259 | <1% | 1,811 | $118.52 | |
| 0320 | <1% | 1,242 | $110.05 | |
| 90999 | Dialysis (unlisted procedure) | <1% | 18 | $101.44 |
| 84100 | <1% | 37 | $91.12 | |
| 0343 | <1% | 383 | $77.45 | |
| 0482 | <1% | 119 | $74.34 | |
| 80061 | Lipid panel | <1% | 12 | $71.91 |
| 84439 | <1% | 13 | $63.93 | |
| 99072 | <1% | 50 | $57.90 | |
| 86140 | <1% | 12 | $54.19 | |
| 0302 | <1% | 2,444 | $49.71 | |
| 0460 | <1% | 460 | $49.60 | |
| 0471 | <1% | 471 | $43.03 | |
| 0410 | <1% | 2,458 | $31.69 | |
| 0424 | <1% | 621 | $26.13 | |
| 0434 | <1% | 240 | $19.50 | |
| 0946 | <1% | 126 | $3.09 | |
| 0760 | 0% | 15 | $0.00 | |
| 0390 | 0% | 71 | $0.00 | |
| 0361 | 0% | 140 | $0.00 | |
| 0312 | 0% | 269 | $0.00 | |
| 0510 | 0% | 78 | $0.00 | |
| 0121 | 0% | 75 | $0.00 | |
| 0381 | 0% | 12 | $0.00 | |
| 0412 | 0% | 44 | $0.00 | |
| 96379 | 0% | 21 | $0.00 | |
| 0720 | 0% | 600 | $0.00 | |
| Q4051 | Splint supplies, miscellaneous (includes thermoplastics, strapping, fasteners, padding and other supplies) | 0% | 51 | $0.00 |
| 0440 | 0% | 184 | $0.00 | |
| S9445 | Patient education, not otherwise classified, non-physician provider, individual, per session | 0% | 126 | $0.00 |
| 0612 | Calcium glucon (wg critical) | 0% | 30 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDOAN, CHRISTOPHER (CHIEF COMPLIANCE COUNSEL)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.